Biogen, Inc. (BIIB)
218.11
+1.33
(+0.61%)
USD |
NASDAQ |
Aug 24, 16:00
218.11
0.00 (0.00%)
After-Hours: 20:00
Biogen Price to Book Value : 1.709 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.699 |
| August 20, 2026 | 1.680 |
| August 19, 2026 | 1.736 |
| August 18, 2026 | 1.666 |
| August 17, 2026 | 1.639 |
| August 14, 2026 | 1.644 |
| August 13, 2026 | 1.651 |
| August 12, 2026 | 1.637 |
| August 11, 2026 | 1.598 |
| August 10, 2026 | 1.623 |
| August 07, 2026 | 1.630 |
| August 06, 2026 | 1.616 |
| August 05, 2026 | 1.619 |
| August 04, 2026 | 1.634 |
| August 03, 2026 | 1.582 |
| July 31, 2026 | 1.590 |
| July 30, 2026 | 1.629 |
| July 29, 2026 | 1.640 |
| July 28, 2026 | 1.611 |
| July 27, 2026 | 1.568 |
| July 24, 2026 | 1.584 |
| July 23, 2026 | 1.572 |
| July 22, 2026 | 1.550 |
| July 21, 2026 | 1.592 |
| July 20, 2026 | 1.567 |
| Date | Value |
|---|---|
| July 17, 2026 | 1.614 |
| July 16, 2026 | 1.637 |
| July 15, 2026 | 1.546 |
| July 14, 2026 | 1.504 |
| July 13, 2026 | 1.638 |
| July 10, 2026 | 1.561 |
| July 09, 2026 | 1.559 |
| July 08, 2026 | 1.570 |
| July 07, 2026 | 1.612 |
| July 06, 2026 | 1.634 |
| July 02, 2026 | 1.694 |
| July 01, 2026 | 1.644 |
| June 30, 2026 | 1.693 |
| June 29, 2026 | 1.714 |
| June 26, 2026 | 1.710 |
| June 25, 2026 | 1.598 |
| June 24, 2026 | 1.580 |
| June 23, 2026 | 1.560 |
| June 22, 2026 | 1.580 |
| June 18, 2026 | 1.556 |
| June 17, 2026 | 1.572 |
| June 16, 2026 | 1.548 |
| June 15, 2026 | 1.572 |
| June 12, 2026 | 1.583 |
| June 11, 2026 | 1.582 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 23.36 |
| AbbVie, Inc. | -- |
| Gilead Sciences, Inc. | 15.40 |
| Vertex Pharmaceuticals, Inc. | 6.854 |
| Amgen, Inc. | 20.53 |
Price to Book Value Related Metrics
| PE Ratio | 38.63 |
| PS Ratio | 3.335 |
| Price to Free Cash Flow | 12.94 |
| Price | 218.11 |
| Earnings Yield | 2.59% |
| Market Cap | 32.21B |
| Operating PE Ratio | 17.11 |
| Normalized PE Ratio | 23.87 |